organ growth ahead cse driven
nutrit epd devic guid
in-lin reiter outperform rais target
strong organ growth upsid nutrit epd devic rais
price continu earn favorit name like beat rank
deliv anoth strong quarter vs estim driven nutrit
devic epd pleas see recent investor sentiment survey management
continu execut org growth guidanc posit stock
continu outperform univers next twelv month libr mitraclip
lab diagnost fire cylind stabl trend nutrit epd
see broad base momentum take stock higher reiter outperform
rate increas price target
libr mitraclip remain growth driver us lab libr grew
end year sale approach bil drive ww diabet growth
management acknowledg approv libr take longer expect
compani remain confid approv includ icgm design mitraclip
quarter end mil sale management expect
coverag fmr drive growth upcom structur heart growth driver
includ triclip well tendyn expect updat throughout
lab strong without full benefit alin therefor continu
see potenti acceler busi us launch hit stride
guidanc in-lin org growth guidanc ep guidanc
in-lin expect management also call org growth around
chang model make minor chang model increas
sale org growth in-lin management guidanc ep estim
beyond remain unchang
valuat target price base ebitda multipl
estim ebitda bil unch new target multipl
abt current trade multipl risk stabil epd em fx product
valuat metric
number share
 close
legal entiti disclosur statu non-u analyst us disclosur credit suiss seek busi
compani cover research report result investor awar firm may conflict interest could
affect object report investor consid report singl factor make invest decis
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
price
global manufactur provid diversifi
healthcar product medic devic equip area
endovascular structur heart
one-year valuat scenario base
ev/ebitda ebitda bil
scenario base emerg segment deliv
growth high-growth segment grow growth grow
one-year valuat grey scenario base
ev/ebitda grey ebitda bil grey
scenario base emerg segment deliv growth
high-growth segment grow growth grow
 close
addit detail takeaway
nutrit bil mil y/i cc
ww pediatr nutrit sale bil mil increas organ
reflect unfavor fx perform led pediasur
pedialyt continu see strong uptak ww adult nutrit sale mil
mil increas organ perform quarter driven strong growth
ensur glucerna diabet specif nutrit brand addit segment
help strong growth across sever countri includ southeast asia latin america
manag expect growth around full year
diagnost bil in-lin y/i cc
organ vs cse organ
laboratori diagnost sale bil mil increas
organ led above-market growth ww result continu strong adopt alin
 well ou molecular diagnost sale mil mil decreas
organ basi sale reflect unfavor fx impact point
diagnost sale mil mil decreas includ
unfavor fx impact rapid diagnost sale mil mil increas
organ organ sale growth led infecti diseas test
develop market cardio-metabol test global partial off-set lower infecti
diseas test sale africa manag expect diagnost grow mid-to-high singl
digit
establish pharma bil mil y/i
cc organ vs cse
sale key emerg market india brazil russia china increas
organ basi reflect unfavor fx last quarter em
sale increas organ includ unfavor fx impact growth
segment led sever geographi latin america asia manag expect
mid-to-high singl digit growth
devic bil mil y/i
cc organ vs cse
electrophysiolog mil growth led strong perform cardiac diagnost
ablat cathet heart failur mil growth driven market adopt
heartmat lvad follow fda approv destin long-term use therapi late
growth structur heart mil led mitraclip grew ww
organ compani also recent initi clinic trial
compar effect mitraclip open heart mitral valv surgic repair peopl
primari mitral regurgit elig open-heart surgeri repair mr prospect
random clinic trial enrol patient site canada europ
evalu effect mitraclip devic moderate-surgical-risk patient
sever primari mr candid open-heart surgeri compani also expect
receiv ce mark approv triclip repair leaki tricuspid heart valv tendyn
target replac mitral valv well approv portico
diabet mil sale increas organ led on-going uptak
freestyl libr report world-wide sale mil organ manag
 oper margin slightli
estim bp
base analysi earn sale net cog lower non-op incom
tax partial off-set higher sg deliv in-lin ep
manag issu organ sale growth guidanc estim potenti fx
headwind compani also forecast gross margin ratio roughli
sg net interest expens expect mil
non-oper incom mil expect adjust tax rate
full year management expect ep rang
expect ep organ sale growth fx
expect exchang neg impact sale management guid gross
margin sg
estimate bpop bpnon-op bpnet chg y/i charl martineau pm univers toronto januari
figur revenu summari varianc analysi
salesy/i chg cc cg org cg salesy/i chg cc cg org cg nutrit emer charl martineau pm univers toronto januari
chang model
increas sale estim ep estim remain
unchang in-lin new guidanc also made adjust top-lin
project beyond increas sale estim per year averag
figur chang model
compani mention price
matt miksic vik chopra certifi respect compani secur individu analyz view express
report accur reflect person view subject compani secur part
compens directli indirectli relat specif recommend view express report
